Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKesson
Harvard Business School
Baxter
Merck
AstraZeneca
Express Scripts

Last Updated: October 15, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR VESICARE

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Vesicare

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00333112 A Study to Evaluate Solifenacin Succinate in Combination With Tamsulosin for the Treatment of Residual Overactive Bladder Symptoms (OAB) in Men. Completed Astellas Pharma Inc Phase 4 2006-05-01 A study to evaluate solifenacin succinate in combination with tamsulosin for the treatment of residual OAB symptoms in men.
NCT00368706 A Double-Blind, Paralleled Study Comparing Efficacy/Safety of Solifenacin to Tolterodine in Overactive Bladder Patients Completed Astellas Pharma Inc Phase 3 2006-09-01 To evaluate the efficacy and safety of solifenacin succinate (Vesicare) 5mg OD in subjects with overactive bladder compared to tolterodine wmg, bid
NCT00431041 Study to Compare the Safety and Efficacy of Solifenacin With Oxybutynin for the Treatment of Overactive Bladder (VECTOR) Completed Astellas Pharma Canada, Inc. Phase 4 2006-12-01 The purpose of this study is to compare the safety and efficacy of solifenacin with oxybutynin immediate-release (IR) for the treatment of overactive bladder (OAB).
NCT00431041 Study to Compare the Safety and Efficacy of Solifenacin With Oxybutynin for the Treatment of Overactive Bladder (VECTOR) Completed Astellas Pharma Inc Phase 4 2006-12-01 The purpose of this study is to compare the safety and efficacy of solifenacin with oxybutynin immediate-release (IR) for the treatment of overactive bladder (OAB).
NCT00454740 Efficacy & Safety Study of VESIcare® (Solifenacin Succinate) in Patients Wishing to Switch From Detrol LA® for Treatment of Overactive Bladder Completed Astellas Pharma Inc Phase 3 2004-06-01 To evaluate the efficacy of 5 and10mg solifenacin succinate in patients with urgency who have OAB syndrome (urgency, with or without urge incontinence, usually with frequency and nocturia) and wish to switch from tolterodine tartrate extended release to solifenacin succinate due to lack of sufficient improvement in urgency episodes
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Vesicare

Condition Name

Condition Name for Vesicare
Intervention Trials
Overactive Bladder 20
Urinary Bladder, Overactive 10
Urinary Incontinence 6
Overactive Bladder Syndrome 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Vesicare
Intervention Trials
Urinary Bladder, Overactive 35
Urinary Incontinence 9
Enuresis 9
Urinary Incontinence, Urge 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Vesicare

Trials by Country

Trials by Country for Vesicare
Location Trials
United States 242
Canada 17
Korea, Republic of 8
United Kingdom 4
Czech Republic 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Vesicare
Location Trials
California 11
Illinois 9
Texas 9
Pennsylvania 9
Florida 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Vesicare

Clinical Trial Phase

Clinical Trial Phase for Vesicare
Clinical Trial Phase Trials
Phase 4 23
Phase 3 9
Phase 2/Phase 3 1
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Vesicare
Clinical Trial Phase Trials
Completed 36
Recruiting 6
Terminated 5
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Vesicare

Sponsor Name

Sponsor Name for Vesicare
Sponsor Trials
Astellas Pharma Inc 20
Astellas Pharma Korea, Inc. 6
Astellas Pharma Europe B.V. 4
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Vesicare
Sponsor Trials
Other 40
Industry 39
NIH 3
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Moodys
Dow
McKesson
Boehringer Ingelheim
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.